JACKSONVILLE, Fla., Nov 2, 2022 — RedDress, a privately held U.S. and Israel-based global medical device company, today announced their new wound care management system –ActiGraft+® system, will be commercially available in Puerto Rico. The product has been approved by MMM, Puerto Rico’s largest insurance provider, and the company has entered into a new distribution partnership with GSN Medical.


ActiGraft+ enables health care providers to produce – in real time – in vitro blood clots from a patient’s own blood. Once applied, the blood clot serves as a protective covering and supports the body’s natural wound healing response. ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds and post-surgical wounds.


“Receiving our approval from MMM provides a pathway to bring ActiGraft+ to patients in Puerto Rico,” said Robert Mueller, General Manager of RedDress. “All patients with chronic wounds deserve access to technologies that will significantly improve their wounds and well-being. We are looking forward to working with GSN Medical to bring high-quality wound care products to hospitals around the territory.


“ActiGraft+ is a great product. During the trials with our MMM Medicare Advantage patients, we had extraordinary results. We are looking forward to treating our Puerto Rican patients and giving them a better quality of life,” said Dr. Orlando Rodriguez-Cabrera, Surgical and Wound Medical Director at MSO.


According to the International Diabetes Federation, approximately 20% of the adult population in Puerto Rico has been diagnosed with diabetes1. With 15-25% of diabetics developing diabetic foot ulcers2 -- they are one of the most common complications of diabetes. Using an advanced wound care product, like ActiGraft, can help physicians better manage the wound so it does not progress.


RedDress launched ActiGraft in the U.S. and Israel and has been working to commercialize ActiGraft globally. ActiGraft is currently available in more than 40 countries including; the United Kingdom, Hong Kong, Italy, South Africa and Brazil. For more information on RedDress’ international growth, visit:



About the Suite of ActiGraft Products

ActiGraft and ActiGraft+, based on RedDress’ proprietary patented technology, are FDA-cleared wound care solutions that enable health care providers to produce – in real time – an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.


ActiGraft and ActiGraft+ are intended for exuding cutaneous wounds. The systems include blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit


About RedDress

RedDress ( is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida.  Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, we’re proud to expand our suite of products to include ActiGraft and our latest innovation - ActiGraft+.



ActiGraft+® system is a registered trademark of RedDress Ltd.

1 International Diabetes Federation

2 Oliver TI, Mutluoglu M. 2022 Aug 8. Diabetic Foot Ulcer Available from:


Subscribe for Updates

"*" indicates required fields